Does Nattokinase Help Arthritis?

"Does nattokinase help arthritis?" is a fair question — both nattokinase and arthritis involve inflammation, both attract heavy supplement marketing, and both sit at the intersection where cardiovascular research and joint research overlap.

The honest scientific answer is narrower than the marketing suggests. Arthritis affects roughly 53 million US adults, but no published human trial has tested nattokinase specifically for arthritis outcomes. What we have is mechanism data — and that is not the same thing as evidence it works.

Table of Contents

1. What "Does Nattokinase Help Arthritis?" Is Really Asking
2. What the Human Evidence Actually Shows
3. How Nattokinase Might Touch Inflammation — in the Lab
4. The Enzymes That Do Have Arthritis Evidence
5. Safety Considerations if You Have Arthritis
6. If You Still Want to Try Nattokinase
7. About BioAbsorb Nattokinase Enzyme
8. Frequently Asked Questions
9. Conclusion

What "Does Nattokinase Help Arthritis?" Is Really Asking

Behind this search question there are usually one of three things going on. Someone with joint pain has read about nattokinase's anti-inflammatory reputation and wonders if it applies to their situation. Someone already taking nattokinase for cardiovascular reasons wants to know if it's also doing joint work in the background. Or someone shopping for a natural arthritis supplement has landed on nattokinase in a comparison article and wants a straight answer.

All three deserve the same answer: nattokinase's evidence base is cardiovascular, not joint. The 2018 pharmacological review covers fibrinolysis, blood pressure, atherosclerosis, lipid modulation, and platelet effects. Arthritis is not on that list — and it is not on that list because the human studies have not been done, not because the enzyme has been tested and failed.

That distinction matters. "No evidence of effect" is not the same as "evidence of no effect." But for anyone considering a supplement to help with an actual arthritis diagnosis, the practical implication is identical: there is no clinical proof that nattokinase will help your joints, and that fact should shape your expectations.

What the Human Evidence Actually Shows

The strongest nattokinase clinical trial to date is the double-blinded Nattokinase Atherothrombotic Prevention Study: 265 participants, median age 65, randomized to 2,000 FU nattokinase or placebo, followed for a median of three years. The primary outcome was progression of subclinical atherosclerosis measured by carotid ultrasound. Secondary outcomes included blood pressure, lipids, coagulation and fibrinolysis factors, inflammatory markers, and monocyte activation markers.

Two things are useful here. First, the trial actually measured inflammatory markers in a nattokinase-treated population — the most directly relevant data we have — and the result was a null finding on the disease endpoint. Second, this was a healthy, low-cardiovascular-risk population. Neither the design nor the participants tell us anything about people with active joint inflammation.

The other frequently cited human study is a 1,062-participant observational study in China that used 10,800 FU/day for 12 months to track carotid atherosclerosis and lipid changes. It reported improvements in carotid intima-media thickness and lipid profiles at that higher dose. Once again — cardiovascular endpoints. No arthritis measurement. No pain scores. No joint function assessment.

Beyond these, most nattokinase safety data comes from vascular disease populations. A real-world clinical study in vascular surgery patients at 100 mg/day showed clinical symptom improvement at 30 days with no drug interactions recorded — again, useful for a cardiovascular indication, silent on joints.

How Nattokinase Might Touch Inflammation — in the Lab

The mechanism case for nattokinase and inflammation is genuinely interesting, and it is what fuels the arthritis question in the first place. It just needs to be understood for what it is: preclinical.

A 2024 endothelial-cell study from Taipei Medical University found that nattokinase treatment induced autophagy and inhibited the NLRP3 inflammasome — a major driver of chronic sterile inflammation — through activation of SRF and THBS1 signalling. The NLRP3 inflammasome is a legitimate target in inflammatory arthritis research, so this is not a trivial finding. But it is a finding in vascular endothelial cells in a dish, not in synovial tissue in a patient.

In animal models, high-dose nattokinase significantly inhibited C-reactive protein rises in streptozotocin-diabetic rats at day 7, though the effect had faded by day 14. A 2024 narrative review in Expert Review of Cardiovascular Therapy synthesizes these findings and proposes nattokinase as a potential adjuvant for inflammation and oxidative stress in non-communicable disease — while explicitly noting that clinical translation is limited.

The gap between "reduces CRP in a diabetic rat" and "reduces pain in a person with knee osteoarthritis" is enormous. Every supplement category has anti-inflammatory mechanism papers that never survive contact with a properly designed human trial. Until nattokinase is tested against actual arthritis endpoints, mechanism is a hypothesis, not evidence.

The Enzymes That Do Have Arthritis Evidence

If your interest in nattokinase is really an interest in oral enzyme therapy for joint pain, you should know the honest picture. There is a proteolytic enzyme combination with clinical arthritis evidence, and it is not nattokinase — it is bromelain paired with trypsin and rutin (rutoside).

Memorial Sloan Kettering summarizes the evidence directly: in a randomized trial of subjects with moderate-to-severe knee osteoarthritis, oral proteolytic enzymes had effectiveness comparable to diclofenac in relieving pain and increasing function. This is not a single study but a small consistent line of trials in knee and temporomandibular osteoarthritis.

A recent 2025 proof-of-mechanism crossover RCT tested the same enzyme combination against placebo in symptomatic knee OA over 8 weeks. It reported reductions in pain, systemic inflammation markers, and urinary CTX-II — a cartilage turnover marker. This is not yet the level of evidence that would put oral enzymes in a rheumatology treatment guideline, but it is the current, published, arthritis-specific evidence line for oral enzyme therapy.

Nattokinase is not part of this line of research. It is not that nattokinase has been tested for arthritis and found inferior — it is that the arthritis question has never been asked of it in a controlled trial. When you see nattokinase marketed for "inflammation" or "joint support," the underlying evidence being borrowed is either the bromelain-trypsin-rutin literature or the cardiovascular inflammation literature, neither of which was designed to answer your question.

Safety Considerations if You Have Arthritis

Even setting aside the efficacy question, arthritis patients have a specific safety concern that people considering nattokinase should understand.

Nattokinase is fibrinolytic — it breaks down fibrin and inhibits PAI-1, which is precisely how it may support cardiovascular health. That same mechanism is the source of its main interaction risk. Memorial Sloan Kettering and the Drugs.com professional monograph both list anticoagulants, antiplatelet agents, and daily aspirin as significant interaction concerns, with a documented case report of cerebellar hemorrhage in a patient combining nattokinase with aspirin who had a history of ischemic stroke.

Arthritis patients are frequently on medications that this concern touches. NSAIDs like ibuprofen and naproxen have antiplatelet effects. Daily low-dose aspirin is common for cardiovascular co-management in older arthritis patients. Some rheumatoid arthritis patients on biologics or DMARDs have additional platelet or coagulation considerations. Adding a fibrinolytic supplement to any of these is not a decision to make casually.

Small short-term trials of nattokinase alone have reported no adverse reactions, and the vascular surgery study noted above found the enzyme well tolerated. But those were not people simultaneously taking NSAIDs or aspirin. If you have arthritis and want to try nattokinase, that conversation belongs with your physician or pharmacist, not with a blog post.

If You Still Want to Try Nattokinase

Some readers will land here still wanting to try nattokinase — because the mechanism story is intriguing, because they want a cardiovascular support benefit as well, or because they have already talked to their doctor and are simply confirming what they know. That is a defensible choice, provided expectations are calibrated.

The dose used in most human research is 2,000 FU (roughly 100 mg) once daily. Anything much lower has thin pharmacokinetic support; anything much higher tips further into theoretical bleeding-risk territory. Take it on an empty stomach so it clears the stomach quickly — the enzyme is sensitive to gastric acid, which is why capsule format matters. Do not expect a joint-specific benefit inside the first weeks or months; you may not get one at all. Be honest with yourself and any healthcare provider you see about the fact that you are taking it.

For a fuller picture of what nattokinase is and how it works, our pillar guide covers the science in depth: see What Is Nattokinase? The Complete Guide to Benefits, Dosage, and Safety. For dose-specific guidance and timing, the Nattokinase Dosage Guide walks through the FU units, timing, and cycling considerations in more detail.

About BioAbsorb Nattokinase Enzyme

BioAbsorb Nutraceuticals is a Canadian brand focused on evidence-based formulations for cardiovascular, immune, and metabolic health. The BioAbsorb Nattokinase Enzyme is formulated around the delivery problem that undermines many nattokinase products: the enzyme is highly sensitive to gastric acid, so how you protect it in transit determines how much active enzyme reaches the bloodstream.

Each capsule contains 100 mg of nattokinase extract standardized to 2,000 FU of fibrinolytic activity — the dose used in the landmark randomized cardiovascular trial and the threshold established for measurable fibrinolytic effect in pharmacokinetic research. Rather than a phthalate-containing enteric coating, BioAbsorb uses DRcaps delayed-release vegetarian capsules, which shield the enzyme through the stomach and release it in the small intestine without the plasticizers common to enteric coatings.

The formula is non-GMO, vitamin K2-free (a deliberate choice — natural natto is high in K2, which partially offsets the fibrinolytic effect and complicates warfarin interaction), and free of gluten, nuts, eggs, dairy, and animal products. Manufacturing is in a Canadian GMP-certified facility. Each bottle holds [CONFIRM BOTTLE SIZE] capsules — a [CONFIRM SUPPLY DURATION] supply at one capsule per day — at [CONFIRM PRICE], roughly [CONFIRM PER-DAY COST] per day.

To be clear: BioAbsorb positions this product for cardiovascular support based on the actual research base, not for arthritis. If you have joint pain as your primary concern, the honest answer this article makes is that other supplements have stronger evidence for that use case — talk to your healthcare provider.

Frequently Asked Questions

Does nattokinase reduce joint pain?

No published human trial has tested nattokinase against joint pain endpoints. Some animal and cell studies show anti-inflammatory activity, but those results have not been translated into pain or function measurements in people with arthritis. If joint pain relief is your goal, discuss options with evidence in that space — such as bromelain-trypsin-rutin combinations, physical therapy, and standard medical management — with your clinician.

Can nattokinase treat rheumatoid arthritis?

Nattokinase has not been studied as a treatment for rheumatoid arthritis, and it should not be considered one. Rheumatoid arthritis is an autoimmune disease that requires medical management, typically with DMARDs and biologics. Adding a fibrinolytic supplement without physician oversight is particularly risky for RA patients, given medication interactions and the disease's own vascular and coagulation considerations.

Is it safe to take nattokinase with NSAIDs like ibuprofen?

Combining nattokinase with NSAIDs is not clearly established as safe. NSAIDs have antiplatelet effects, and nattokinase adds a fibrinolytic effect on top of that — potentially compounding bleeding risk. Memorial Sloan Kettering explicitly flags aspirin and antiplatelet drugs as interaction concerns. Anyone taking daily NSAIDs for arthritis should get medical guidance before adding nattokinase.

What enzyme supplement has the best evidence for arthritis?

The oral enzyme combination with the strongest arthritis evidence is bromelain paired with trypsin and rutin. Small randomized trials in knee osteoarthritis and temporomandibular joint osteoarthritis have shown pain and function improvements comparable to diclofenac. This is still not a first-line therapy in rheumatology guidelines, but it is the enzyme approach with actual arthritis-specific human data — nattokinase is not.

Should I try nattokinase if my arthritis is inflammation-driven?

The reasoning is understandable, but the evidence to support it is not there. Nattokinase's anti-inflammatory activity is documented in lab settings, not in joint conditions. If your arthritis is inflammatory and you want to explore supplement options with better rationale, discuss omega-3s, curcumin, or oral enzyme therapy with your healthcare provider — all have more direct evidence for inflammation-driven joint pain than nattokinase does.

How is nattokinase different from serrapeptase for joint issues?

Both are proteolytic enzymes derived from bacteria, but their research profiles differ. Nattokinase is best studied for fibrinolysis and cardiovascular endpoints. Serrapeptase has a longer history of use for inflammation and post-surgical swelling in some regions, though its evidence base is also thin and inconsistent by modern standards. Neither has robust modern arthritis trials.

Conclusion

Nattokinase is a real enzyme with a real evidence base — it is just a cardiovascular evidence base, not an arthritis one. If your primary interest is joint pain, the honest scientific answer is that other options have better data, and combining nattokinase with common arthritis medications carries interaction risks worth taking seriously. If your interest is cardiovascular and you happen to have arthritis, that is a different conversation — BioAbsorb Nattokinase Enzyme is formulated for that use case, and your healthcare provider is the right person to help you weigh whether it fits your situation.

Research References

1. Hodis HN, et al. Nattokinase atherothrombotic prevention study: A randomized controlled trial. Clinical Hemorheology and Microcirculation. 2021;78(4):339–353. https://pubmed.ncbi.nlm.nih.gov/33843667/
2. Fallon EA, et al. Prevalence of Diagnosed Arthritis — United States, 2019–2021. MMWR Morbidity and Mortality Weekly Report. 2023;72(41):1101–1107. https://www.cdc.gov/mmwr/volumes/72/wr/mm7241a1.htm
3. Berenbaum F. Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis. Nature Reviews Rheumatology. 2016;12(10):580–592. https://www.nature.com/articles/nrrheum.2016.136
4. Chiu HW, et al. Nattokinase attenuates endothelial inflammation through the activation of SRF and THBS1. International Journal of Biological Macromolecules. 2024;268(Pt 2):131779. https://pubmed.ncbi.nlm.nih.gov/38679250/
5. Yamaguchi M, Fukuyama R, Fujita M. Effect of nattokinase on the pathological conditions in streptozotocin-induced diabetic rats. Heliyon. 2024;10(7):e28835. https://pubmed.ncbi.nlm.nih.gov/38586318/
6. Mafra D, et al. Nattokinase as an adjuvant therapeutic strategy for non-communicable diseases: a review of fibrinolytic, antithrombotic, anti-inflammatory, and antioxidant effects. Expert Review of Cardiovascular Therapy. 2024;22(10):565–574. https://www.tandfonline.com/doi/abs/10.1080/14779072.2024.2416663
7. Chen H, et al. Nattokinase: A promising alternative in prevention and treatment of cardiovascular diseases. Biomarker Insights. 2018;13:1177271918785130. https://journals.sagepub.com/doi/10.1177/1177271918785130
8. Memorial Sloan Kettering Cancer Center. Nattokinase — About Herbs. https://www.mskcc.org/cancer-care/integrative-medicine/herbs/nattokinase
9. Memorial Sloan Kettering Cancer Center. Proteolytic Enzymes — About Herbs. https://www.mskcc.org/cancer-care/integrative-medicine/herbs/proteolytic-enzymes
10. Kloppenburg M, et al. Oral enzyme combination therapy reduces systemic inflammation, urinary CTXII and pain in knee osteoarthritis: a proof-of-mechanism, randomised, crossover, double-blind, placebo-controlled trial. 2025 (NCT05038410). https://pubmed.ncbi.nlm.nih.gov/40803821/
11. Drugs.com. Nattokinase — Professional Monograph. https://www.drugs.com/npp/nattokinase.html
12. Gallelli L, et al. Data recorded in real life support the safety of nattokinase in patients with vascular diseases. Biomedicines. 2021;9(6):667. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8231931/
13. Chen H, Chen J, Zhang F, et al. Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants. Frontiers in Cardiovascular Medicine. 2022;9:964977. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9441630/

About the Author

David Kimbell is a health writer, digital entrepreneur and former aerospace engineer, based in Ottawa, Canada. He loves translating complex science into clear, actionable guidance for consumers seeking evidence-based solutions.

---

Important Disclaimers

Medical Disclaimer: This article provides educational information only and is not intended as medical advice. Always consult with a qualified healthcare provider before starting any new supplement, especially if you have existing health conditions, take medications, or are pregnant or nursing.

FDA/Health Canada Statement: These statements have not been evaluated by the Food and Drug Administration or Health Canada. This product is not intended to diagnose, treat, cure, or prevent any disease.